Page last updated: 2024-08-24

pyrrolidine dithiocarbamate and Experimental Mammary Neoplasms

pyrrolidine dithiocarbamate has been researched along with Experimental Mammary Neoplasms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheng, X; He, L; Li, D; Sun, M; Tang, R; Wang, X; Zheng, Y1

Other Studies

1 other study(ies) available for pyrrolidine dithiocarbamate and Experimental Mammary Neoplasms

ArticleYear
Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
    Colloids and surfaces. B, Biointerfaces, 2019, Sep-01, Volume: 181

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Doxorubicin; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; HEK293 Cells; Humans; Hydrodynamics; Hydrogen-Ion Concentration; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Particle Size; Polymers; Pyrrolidines; Surface Properties; Thiocarbamates

2019